ORIC
NASDAQ · Biotechnology
Oric Pharmaceuticals Inc
$8.82
+0.33 (+3.89%)
Open$8.61
Previous Close$8.49
Day High$8.93
Day Low$8.50
52W High$14.68
52W Low$7.23
Volume—
Avg Volume2.80M
Market Cap913.70M
P/E Ratio—
EPS$-1.35
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+492.5% upside
Current
$8.82
$8.82
Target
$52.26
$52.26
$31.55
$52.26 avg
$71.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 151.33M | 156.80M | 123.33M |
| Net Income | -16,895,209 | -20,414,835 | -15,522,009 |
| Profit Margin | -11.2% | -13.0% | -12.6% |
| EBITDA | -22,168,918 | -26,679,727 | -20,408,682 |
| Free Cash Flow | -10,591,679 | -9,966,569 | -9,555,180 |
| Rev Growth | +7.8% | +20.1% | +4.2% |
| Debt/Equity | 0.36 | 0.45 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |